[ad_1]
Published on: Amended:
France recommended on Friday that people who have already recovered from Covid-19 receive a single dose of the vaccine, becoming the first country to issue such advice.
The three Covid-19 vaccines approved for use in the European Union are given as two doses, given several weeks apart.
This is because clinical trials have shown that immunity to the disease is significantly higher after individuals receive two injections.
However, the French public health authority said on Friday that people who had previously been infected with Covid-19 developed an immune response similar to that conferred by a dose of vaccine, and that a single dose after infection would likely suffice. .
“A single dose of the vaccine will also play the role of reminding” their immune system how to fight Covid-19, he said.
The authority recommended an interval of three to six months after infection before people who had recovered from Covid-19 receive a stroke.
“At the moment, no country has clearly positioned itself in terms of a single dose of vaccination for people who have already contracted Covid-19,” he said.
The vaccination program has only just begun
France has accelerated its vaccination program in recent weeks but it is only in its early stages.
As of Thursday, more than 2.1 million people had received at least one dose of the vaccine, of which nearly 535,800 had already received two.
At least 3.4 million people have had confirmed Covid-19 infections in France, although there likely were many more given the relative lack of accessible tests during the first wave of the pandemic.
Two recent US studies suggest that a single dose of the vaccine may work in people who have already recovered from Covid-19.
One article said immunity in people who had had Covid-19 and then received a single dose of the vaccine “is equal to or even greater” than in people who did not have Covid-19 but received two vaccine doses.
A vaccine still in development by Johnson & Johnson works with a single dose, but it has yet to receive emergency use clearance from European and US regulators.
(AFP)
[ad_2]
Source link